-+ 0.00%
-+ 0.00%
-+ 0.00%

Abivax issues correction to release on ABTECT maintenance Part 2 results for ulcerative colitis drug obefazimod

PUBT·06/29/2026 20:47:50
Listen to the news
Abivax issues correction to release on ABTECT maintenance Part 2 results for ulcerative colitis drug obefazimod
  • Abivax issued a correction to its June 29 release on ABTECT Phase 3 maintenance Part 2 results for obefazimod in ulcerative colitis.
  • The corrected release highlights Week 44 outcomes in induction non-responders on 50 mg: 37.2% clinical remission, 34.5% endoscopic remission.
  • It also reiterates a dose-escalation effect, with 45.5% clinical remission in relapsed patients whose dose increased to 50 mg.
  • Updated exposure-adjusted cancer incidence rates remained within expected ulcerative colitis reference ranges across integrated Phase 2-3 datasets.
  • The company kept its target to file a U.S. NDA for obefazimod in ulcerative colitis in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via EQS News (Ref. ID: fr_reg_2356358_fr) on June 29, 2026, and is solely responsible for the information contained therein.